Panel Discussion: Overcoming Clinical Bottlenecks in LNP Development by Streamlining Processes for Advancing Safer Drug Products to Patients
- What are the most crucial technical challenges in translating LNP formulations from preclinic to human studies?
- As the field moves from early clinical programs to commercialization, what are the key challenges in translating LNP formulations from small-scale development into robust, large-scale manufacturing processes?
- How to optimize the dosing strategies for LNPs to ensure safe and effective therapeutics?